Link to follow on Amazon :

contact : alizeesa@gmail.com

Background: Non-small cell lung cancer (NSCLC) is a major subtype of lung cancer with poor prognosis. Artemisinin (AN), produced naturally in Artemisia annua L., has anti-cancer activity. Artemisinin delivered as dried leaf Artemisia (DLA) showed efficacy against malaria in rodents and humans.

Hypothesis/purpose: DLA is posited as being at least as efficacious as artesunate (AS) in its ability to induce cytotoxicity in NSCLC cells and also inhibit tumor growth in a NSCLC xenograft murine model

Study design: Three NSCLC cell lines were used, a non-cancerous human fibroblast line, and xenograft murine models to compare efficacy of artemisinin delivered p.o. via DLA, DLA extracts (DLAe), and AS

Methods: DLAe was compared to AS using NSCLC cell lines A549, H1299 and PC9 as well as non-cancerous human dermal fibroblasts (HDF) CCD-1108Sk line. Cell viability, cell migration and cell cycle were compared for AS and DLAe. Westerns measured activated caspases-3, -8 and -9 to determine involvement of intrinsic and/or extrinsic apoptotic pathways. Xenograft murine models of A549 and PC9 cells were used to measure tumor growth inhibition by AS or DLA, with tumor volume the primary endpoint

Résultats : DLAe et AS ont supprimé la viabilité des cellules A549, H1299 et PC9 sans inhibition des cellules HDF CCD-1108Sk non cancéreuses. Les caspases-3, -8 et -9 ont été activées, suggérant que la mort cellulaire a été stimulée par des voies apoptotiques intrinsèques et/ou extrinsèques. Les deux médicaments ont induit un arrêt G2/M ou mitotique dans les cellules PC9 et H1299, et le DLAe a induit un arrêt G1 dans les cellules A549. L'AS et le DLAe ont induit des dommages à l'ADN sous forme de cassures double brin mises en évidence par la phosphorylation de l'histone H2AX. DLAe a inhibé la migration des cellules PC9 et A549. Chez les animaux xénogreffés A549, po AS et DLA ont inhibé la croissance tumorale relative de 40 % et 50 %, respectivement, par rapport aux témoins. L'AS était inefficace pour inhiber la croissance tumorale induite par PC9, mais le DLA inhibait la croissance tumorale relative d'environ 50 % par rapport aux témoins

Conclusion: This is the first study demonstrating efficacy of DLA and mechanistic differences of DLAe vs. AS, against NSCLC cells. Compared to AS, DLA possesses qualities of a novel therapeutic for patients with NSCLC